STOCK TITAN

Dr Reddys Labs Stock Price, News & Analysis

RDY NYSE

Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.

Dr. Reddy's Laboratories (RDY) maintains its position as a global pharmaceutical innovator through strategic developments in generic medicines, biosimilars, and active pharmaceutical ingredients. This news hub provides investors and industry professionals with essential updates on corporate milestones, regulatory filings, and market expansions.

Access real-time information about earnings announcements, partnership agreements, and product pipeline advancements. Our curated collection features official press releases covering FDA approvals, manufacturing facility certifications, and therapeutic area breakthroughs in oncology and gastroenterology.

Monitor critical updates including patent litigation outcomes, emerging market entries, and sustainability initiatives. The repository serves as a reliable resource for understanding RDY's operational strategies and quality compliance across 75+ countries.

Bookmark this page for streamlined access to verified updates about Dr. Reddy's Laboratories. Check regularly for insights into biosimilar developments, API production innovations, and financial performance indicators shaping the global pharmaceutical landscape.

Rhea-AI Summary

Dr. Reddy’s Laboratories released its Q4 & Full Year FY24 Financial Results. In Q4FY24, revenues were ₹70,830 Mn, up 12% YoY, and FY24 revenues were ₹279,164 Mn, up 14% YoY. Gross margin was 58.6%. SG&A expenses increased by 14% YoY, R&D expenses were 9.7% of revenues. EBITDA was 26.4% of revenues. Profit before tax increased by 21% YoY in Q4FY24, and by 19% YoY for FY24. Profit after tax grew by 36% YoY in Q4FY24 and 24% YoY for FY24.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
-
Rhea-AI Summary

Dr. Reddy's Laboratories announced the launch of Doxycycline Capsules, 40 mg in the U.S., a generic equivalent of ORACEA® approved by the USFDA. The capsules contain immediate-release and delayed-release pellets, each totaling 40 mg of anhydrous doxycycline. This launch is a significant development for Dr. Reddy's in the U.S. market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags

FAQ

What is the current stock price of Dr Reddys Labs (RDY)?

The current stock price of Dr Reddys Labs (RDY) is $15.8 as of June 13, 2025.

What is the market cap of Dr Reddys Labs (RDY)?

The market cap of Dr Reddys Labs (RDY) is approximately 12.9B.
Dr Reddys Labs

NYSE:RDY

RDY Rankings

RDY Stock Data

12.92B
832.06M
15.04%
2.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
India
Hyderabad